A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis
Latest Information Update: 29 Mar 2025
At a glance
- Drugs Upadacitinib (Primary) ; Corticosteroids
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms Start Up Japan
- Sponsors AbbVie
Most Recent Events
- 03 Jan 2025 Status changed from not yet recruiting to recruiting.
- 03 Dec 2024 Planned End Date changed from 21 Jan 2027 to 1 Jan 2027.
- 03 Dec 2024 Planned primary completion date changed from 21 Jan 2027 to 1 Jan 2027.